Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.
SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
